西非症状性拉沙病毒感染发病率前瞻性多中心队列研究
BACKGROUND: Lassa fever vaccine trials are hampered by knowledge gaps on disease incidence, at-risk populations, sequelae, and transmission risks.…
要点
- 2-17岁儿童拉沙热风险高于成人,应作为疫苗试验重点人群。
- 拉沙热患者疟疾共感染和听力损失比例高,需纳入社区发热鉴别诊断。
核心结论
- 西非症状性拉沙病毒感染不常见,疫苗 efficacy 试验需大规模人群。
- 儿童拉沙热风险高于成人,应作为试验重点人群。
- 疟疾共感染和感染后听力损失高发,需进一步探索并纳入社区发热管理。
研究设计与样本
- 前瞻性多中心队列研究,在贝宁、利比里亚、尼日利亚和塞拉利昂111个农村社区开展。
- 采用国家特异性随机抽样识别家庭,纳入≥2岁符合条件的家庭成员。
主要发现
- 病死率13%(5/39),疟疾共感染27/39(69%)。
- 出院时听力损失9/28(32%),出院后4个月听力损失14/29(48%)。
关键数值与推荐
- 病死率13%(5/39)。
- 疟疾共感染69%(27/39),出院时听力损失32%(9/28),4个月后48%(14/29)。
临床怎么用
- 在拉沙热流行区社区发热管理中将拉沙热纳入鉴别诊断。
- 针对儿童开展学校健康教育和家庭风险沟通。
- 疫苗试验应重点纳入儿童人群并考虑大规模设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lassa fever vaccine trials are hampered by knowledge gaps on disease incidence, at-risk populations, sequelae, and transmission risks. We aimed to estimate symptomatic Lassa virus infection incidence in endemic areas and determine community Lassa fever case fatality risk (CFR), malaria co-infection, hearing loss in survivors, and household risk factors. METHODS: The Enable 1.0 Lassa Research Study was a prospective, multisite, cohort study conducted in 111 rural communities across Benin, Liberia, Nigeria, and Sierra Leone, with documented Lassa fever transmission. Households were identified using country-specific random sampling approaches, and eligible household members aged at least 2 years were invited to participate following community engagement and informed consent. Eligibility required participants to be afebrile at enrolment, resident in the community for at least 6 months, intending to remain for the study duration, and able and willing to comply with study procedures. Participants were monitored for suspected Lassa fever symptoms over 18-30 months. The blood samples of people with suspected Lassa fever were evaluated for Lassa virus by RT-PCR and malaria by rapid diagnostic test. The hearing status of people who survived Lassa fever was tested at the hospital before discharge and 4 months later. Crude Lassa fever incidence rates (IRs) and rate ratios (IRRs) were estimated using Poisson regressions. Household risk factors were analysed using mixed-effect logistic models. FINDINGS: Between Nov 30, 2020 and Nov 20, 2023, among 20 131 participants, 8183 people with suspected Lassa fever were evaluated, revealing 39 people with Lassa fever, representing an overall Lassa fever IR of 1·27 people with Lassa fever per 1000 person-years (95% CI 0·88-1·84). Lassa fever risk was higher in children aged 2-17 years than in adults (adjusted IRR 1·96, 95% CI 1·04-3·72) but did not differ by sex. CFR was 13% (five of 39). 27 (69%) of 39 people with Lassa fever had malaria co-infection, nine (32%) of 28 had hearing loss at discharge, and 14 (48%) of 29 had hearing loss 4 months after discharge. No household-level characteristics were significantly associated with Lassa fever. INTERPRETATION: Symptomatic Lassa virus infection occurs infrequently in West Africa, meaning large vaccine trials are required to measure efficacy. Trials should target children, who are at higher risk of Lassa fever, alongside the further development of targeted school-based health education and household-level risk communication programmes in endemic communities. The high prevalences of malaria co-infection and hearing loss after infection warrant further exploration in future trials and reinforce the need for integrated community fever management strategies that include Lassa fever as a differential diagnosis. FUNDING: The Coalition for Epidemic Preparedness Innovations.
引用
- Incidence of symptomatic Lassa virus infection in West African countries (Enable 1.0 Lassa Research Study): a prospective, multisite, cohort study. Lancet Glob Health. 2026. PMID: 42379202. doi:10.1016/S2214-109X(26)00090-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。